影响阿尔茨海默病及相关痴呆症韧性与预防的因素
本文综述了可改变风险因素与阿尔茨海默病及相关痴呆症(AD/ADRD)预防及大脑韧性之间的关系。美国食品药品监督管理局已完全批准2种靶向β淀粉样蛋白的单克隆抗体,但适用患者有限且不能阻止疾病进展。估计解决可改变风险因素最多可延迟40%的AD/ADRD病例。
要点
- 解决可改变风险因素最多可能延迟40%的AD/ADRD病例。
- 美国食品药品监督管理局已完全批准2种靶向β淀粉样蛋白的单克隆抗体。
- 这些抗体仅适用于有限的患者亚群且不能阻止疾病进展。
核心结论
- 解决可改变风险因素可能预防AD/ADRD并增加大脑韧性,估计最多可延迟40%的AD/ADRD病例。
研究设计与样本
- 综述,讨论与AD/ADRD预防和/或大脑韧性相关的可改变风险因素。
主要发现
- 美国食品药品监督管理局已完全批准2种靶向β淀粉样蛋白的单克隆抗体,但仅适用于有限患者亚群且不能阻止疾病进展。
- 估计解决可改变风险因素最多可延迟40%的AD/ADRD病例。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Alzheimer's disease (AD) is a devastating, age-associated neurodegenerative disorder and the most common cause of dementia. The clinical continuum of AD spans from preclinical disease to subjective cognitive decline, mild cognitive impairment, and dementia stages (mild, moderate, and severe). Neuropathologically, AD is defined by the accumulation of amyloid β (Aβ) into extracellular plaques in the brain parenchyma and in the cerebral vasculature, and by abnormally phosphorylated tau that accumulates intraneuronally forming neurofibrillary tangles (NFTs). Development of treatment approaches that prevent or even reduce the cognitive decline because of AD has been slow compared to other major causes of death. Recently, the United States Food and Drug Administration gave full approval to 2 different Aβ-targeting monoclonal antibodies. However, this breakthrough disease modifying approach only applies to a limited subset of patients in the AD continuum and there are stringent eligibility criteria. Furthermore, these approaches do not prevent progression of disease, because other AD-related pathologies, such as NFTs, are not directly targeted. A non-mutually exclusive alternative is to address lifestyle interventions that can help reduce the risk of AD and AD-related dementias (ADRD). It is estimated that addressing such modifiable risk factors could potentially delay up to 40% of AD/ADRD cases. In this review, we discuss some of the many modifiable risk factors that may be associated with prevention of AD/ADRD and/or increasing brain resilience, as well as other factors that may interact with these modifiable risk factors to influence AD/ADRD progression. [Color figure can be viewed at www.annalsofneurology.org] ANN NEUROL 2024;96:633-649.
引用
- Masurkar AV, Marsh K, Morgan B, et al. Factors Affecting Resilience and Prevention of Alzheimer's Disease and Related Dementias. Ann Neurol. 2024. PMID: 39152774. doi:10.1002/ana.27055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。